ABPI’s 2025 Medicines Impact and Investment Survey: Unpacking the Challenges Facing the UK Life Sciences Sector

As the sun glimmered over the historical skyline of London, pharmaceutical executives gathered at a high-profile summit, their faces etched with concern. For many, the pressing question reverberating through the hallways was not merely about innovation but about survival. “If we continue down this path, we risk losing our status as a global leader in pharmaceuticals,” said Dr. Emily Harrison, a leading health economist. The urgency stemmed from the findings of the ABPI’s newly released 2025 Medicines Impact and Investment Survey (MIIS)—a clarion call to action highlighting the precarious state of the UK’s life sciences sector.

The Unraveling Landscape of UK Pharma Investments

David Watson, Executive Director of Patient Access at the ABPI, articulated the core findings of the survey that reveal the underlying issues threatening investment and innovation. He stated, “The MIIS underscores a critical reality: high and unpredictable payment rates imposed by the government significantly deter pharmaceutical companies from investing in the UK.” This sentiment echoed through the hall, resonating with the challenges voiced by industry leaders.

The MIIS, launched in September 2025, aimed to offer a deeper understanding of how UK policy impacts companies’ investment decisions, workforce plans, and the prioritization of new medicine launches. As Watson elaborated, “We must recognize where we are losing traction, especially compared to our European counterparts. The stakes are high, not just for companies, but for NHS patients who rely on cutting-edge treatments.”

Key Findings of the MIIS

• Investment Stagnation: Over the past decade, global pharmaceutical R&D investments have seen a 6.6% year-on-year increase. Yet, post-pandemic figures show the UK lagging significantly, with growth stagnating at only 3.2%.
• Launches Impacted: Approximately 20% of pharmaceutical portfolios faced adverse effects on their launch timelines, mirroring data from the National Institute for Health and Care Excellence (NICE) that highlighted a 25% non-launch rate.
• Policy Influence: An overwhelming 90% of companies highlighted that volatile payments and strict NICE thresholds primarily dictated their operational strategies in the UK.

The MIIS reported a noted decline in the UK’s global launch attractiveness. Nearly two-thirds of companies articulated a growing perception of the UK as a “second-wave market,” while late-stage clinical trials became increasingly vulnerable to budgetary cuts and operational halts. The data indicated that since January 2024, 46 new drugs faced either delayed, private, or canceled launches, limiting access to groundbreaking therapies.

Ripple Effects on Patient Care and Clinical Trials

These shifts manifest as troubling realities for NHS patients. “Every delayed launch is not just a statistic. It’s a tangible setback for cancer patients waiting for life-saving treatments,” remarked Dr. Alan Chen, a prominent oncologist. His words cut through the bureaucratic layers, revealing the human cost of policy failures. The MIIS data suggested that half of the disqualified launches would never reach NHS patients; many were cutting-edge treatments in oncology, a field where the UK’s survival rates have consistently lagged behind its global peers.

Companies explain these setbacks create a vicious cycle, reducing investment not only in new therapies but also in the clinical trials essential for future innovations. The MIIS laid bare that 79% of firms had contemplated or executed investment cuts since early 2024, signaling a shift away from the UK as a key location for pharmaceutical research and development.

Factors Behind Investment Decisions

The findings highlighted two critical factors that have increasingly shaped firm decisions:

• High and Volatile Payments: Frequent fluctuations in the Voluntary Scheme for Branded Medicines Pricing (VPAG) have led to uncertainty, thereby affecting expected revenue models for companies operating in the UK.
• NICE Cost-Effectiveness Threshold: The relationship between high rebate rates and low NICE thresholds has discouraged companies from viewing the UK as a viable launch market, diminishing the attractiveness of the region for research and clinical trials.

Watson emphasized that the current stance taken by the UK government regarding these financial mechanics is imperative for rejuvenating interest from global pharmaceutical players: “Stagnating NICE thresholds and unpredictable VPAG rates must become a thing of the past if we are to reclaim our status as a global leader.”

Path Forward: A Call for Reforms

The ABPI survey arrives at a pivotal moment—just ahead of the UK/US pharmaceuticals deal, which promises to address these very issues. Watson expressed cautious optimism: “The government’s commitment to altering the reimbursement landscape is a step in the right direction.” However, he added that real change requires swift and deliberate action, with continued input from industry stakeholders.

The Prime Minister’s assurances regarding the swift implementation of reforms garnered applause from industry veterans, yet many remain skeptical. Dr. Harrison cautioned, “Words need to translate into action. The time is now for the UK to demonstrate that it can attract investment and ensure that NHS patients have access to the best treatments available.”

As the gathered executives left the summit, they carried with them a renewed sense of urgency tempered by hope. The MIIS findings provided not merely a snapshot of challenges but a clarion call for robust debate and immediate reform. The future of the UK life sciences sector hangs in the balance, and as policymakers weigh their next steps, the stakes have never been higher for both investors and patients alike.

Source: www.abpi.org.uk